About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Changqing Co., Ltd. stated on its interactive platform on October 31 that the company's main business is the research, development, production, sales and technical consulting of auto parts and molds, and it has not yet ventured into humanoid robots.

2025-10-31

Changqing Co., Ltd. stated on its interactive platform on October 31 that the company's main business is the research, development, production, sales and technical consulting of auto parts and molds, and it has not yet ventured into humanoid robots.

Other News
2025-10-31

The China Securities Regulatory Commission (CSRC) is soliciting public comments on the "Guidelines on Performance Benchmarks for Publicly Offered Securities Investment Funds (Draft for Comment)." The guidelines consist of six chapters and twenty-one

The China Securities Regulatory Commission (CSRC) is soliciting public comments on the "Guidelines on Performance Benchmarks for Publicly Offered Securities Investment Funds (Draft for Comment)." The guidelines consist of six chapters and twenty-one articles, with the main contents as follows: First, emphasizing the representative role of performance benchmarks, which should reflect the core elements and investment style stipulated in the fund contract and cannot be changed arbitrarily once selected. Second, strengthening the binding role of performance benchmarks, requiring fund managers to establish a full-process internal control mechanism, improve internal decision-making levels, and ensure the stability of investment styles. Third, leveraging the evaluation role of performance benchmarks, standardizing the use of performance benchmarks in areas such as compensation assessment, fund sales, and fund evaluation. Fourth, establishing multiple lines of defense, further strengthening information disclosure and fund custodian supervision on the basis of fund manager self-discipline.
2025-11-01

Pfizer (PFE.N) received early approval from the U.S. Federal Trade Commission (FTC) for its acquisition of obesity drug developer Metsera.

Pfizer (PFE.N) received early approval from the U.S. Federal Trade Commission (FTC) for its acquisition of obesity drug developer Metsera.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2025 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.

Web Design by YSD